<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04708730</url>
  </required_header>
  <id_info>
    <org_study_id>Y (2020) 043</org_study_id>
    <nct_id>NCT04708730</nct_id>
  </id_info>
  <brief_title>Improving Neuroprotective Strategy for Ischemic Stroke After Thrombectomy Followed by DELP (INSIST-DELP)</brief_title>
  <official_title>Improving Neuroprotective Strategy for Ischemic Stroke After Thrombectomy Followed by DELP (INSIST-DELP): a Prospective, Random, Open-label, Blind-endpoint, Multi-centre Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>General Hospital of Shenyang Military Region</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>General Hospital of Shenyang Military Region</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Delipid Extracorporeal Lipoprotein filter from Plasma (DELP) has been found to improve&#xD;
      neurological function and life ability of AIS patients and approved for the treatment of AIS&#xD;
      by China Food and Drug Administration (CFDA). Our recent study imply that the neuroprotective&#xD;
      effect of DELP involved multiple neuroprotective mechanism such as anti-inflammation, free&#xD;
      radical scavenging, and decreasing MMP-9. Based on the multiple mechanisms, DELP was used to&#xD;
      investigate the effect on acute ischemic stroke receiving endovascular treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 15, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with modified Rankin Score 0 to 2</measure>
    <time_frame>Day 90</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with modified Rankin Score 0 to 1</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in national institutes of health stroke scale (NIHSS)</measure>
    <time_frame>48 hours</time_frame>
    <description>NIHSS ranges from 0-42, and the decrease in NIHSS means the improvement of neurological deficit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in national institutes of health stroke scale (NIHSS)</measure>
    <time_frame>7 days</time_frame>
    <description>NIHSS ranges from 0-42, and the decrease in NIHSS means the improvement of neurological deficit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in cerebral infarct volume</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the occurence of stroke or other cardiovascular events</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the occurence of infections post stroke</measure>
    <time_frame>Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of symptomatic intracranial hemorrhage (sICH)</measure>
    <time_frame>48 hours</time_frame>
    <description>sICH was defined as 4 or more increase in NIHSS caused by hemorrhage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of intraparenchymal hemorrhage (PH1 and PH2)</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the occurence of death due to any cause</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>DELP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Delipid Extracorporeal Lipoprotein filter from Plasma (DELP) is a non-pharmacological therapy for acute stroke, which is approved by China Food and Drug Administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Delipid Extracorporeal Lipoprotein filter from Plasma</intervention_name>
    <description>As a non-pharmacological therapy, Delipid Extracorporeal Lipoprotein filter from Plasma (DELP) hase been approved by China Food and Drug Administration to treat acute stroke</description>
    <arm_group_label>DELP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years;&#xD;
&#xD;
          -  acute anterior circulatory cerebral infarction with large vessel occlusion;&#xD;
&#xD;
          -  NIHSS≥6 before endovascular treatment;&#xD;
&#xD;
          -  good recanalization (TICI 2b-3);&#xD;
&#xD;
          -  time from onset to groin puncture is less than 8 hours;&#xD;
&#xD;
          -  time from recanalization to DELP is less than 2 hours;&#xD;
&#xD;
          -  Premorbid mRS 0 or 1;&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  poor recanalization (TICI 1-2a);&#xD;
&#xD;
          -  Coagulation disorders, systematic hemorrhagic tendency, thrombocytopenia （&#xD;
             &lt;100000/mm3;&#xD;
&#xD;
          -  Severe hepatic or renal dysfunction, increase in ALT or AST (more than 2 times of&#xD;
             upper limit of normal value), increase in serum creatinine (more than 1.5 times of&#xD;
             upper limit of normal value) or requiring dialysis;&#xD;
&#xD;
          -  Severe hypertension (systolic blood pressure over 200mmHg or diastolic blood pressure&#xD;
             over 110 mmHg);&#xD;
&#xD;
          -  Previous allergy to heparin or calcium;&#xD;
&#xD;
          -  hypoproteinemia;&#xD;
&#xD;
          -  Unsuitable for this clinical studies assessed by researcher.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Neurology, General Hospital of Northern Theater Command</name>
      <address>
        <city>Shenyang</city>
        <zip>110016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hui-Sheng Chen, Ph.D.</last_name>
      <phone>+86 13352452086</phone>
      <email>chszh@aliyun.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 11, 2021</study_first_submitted>
  <study_first_submitted_qc>January 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>General Hospital of Shenyang Military Region</investigator_affiliation>
    <investigator_full_name>Hui-Sheng Chen</investigator_full_name>
    <investigator_title>Head of Neurology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD will be shared in request after the trial finish and will include study protocol, statistical analysis plan.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

